JP2017509649A5 - - Google Patents

Download PDF

Info

Publication number
JP2017509649A5
JP2017509649A5 JP2016558023A JP2016558023A JP2017509649A5 JP 2017509649 A5 JP2017509649 A5 JP 2017509649A5 JP 2016558023 A JP2016558023 A JP 2016558023A JP 2016558023 A JP2016558023 A JP 2016558023A JP 2017509649 A5 JP2017509649 A5 JP 2017509649A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
seq
dose
body weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016558023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017509649A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/021551 external-priority patent/WO2015143209A1/en
Publication of JP2017509649A publication Critical patent/JP2017509649A/ja
Publication of JP2017509649A5 publication Critical patent/JP2017509649A5/ja
Withdrawn legal-status Critical Current

Links

JP2016558023A 2014-03-19 2015-03-19 Ｃｄ４０ｌに対するドメイン抗体を用いる移植拒絶を治療する方法 Withdrawn JP2017509649A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461955588P 2014-03-19 2014-03-19
US61/955,588 2014-03-19
PCT/US2015/021551 WO2015143209A1 (en) 2014-03-19 2015-03-19 Methods of treating transplant rejection using a domain antibody directed against cd40l

Publications (2)

Publication Number Publication Date
JP2017509649A JP2017509649A (ja) 2017-04-06
JP2017509649A5 true JP2017509649A5 (enExample) 2018-04-05

Family

ID=53055087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016558023A Withdrawn JP2017509649A (ja) 2014-03-19 2015-03-19 Ｃｄ４０ｌに対するドメイン抗体を用いる移植拒絶を治療する方法

Country Status (13)

Country Link
US (2) US20170051059A1 (enExample)
EP (1) EP3119809A1 (enExample)
JP (1) JP2017509649A (enExample)
KR (1) KR20160124912A (enExample)
CN (1) CN106132429A (enExample)
AU (1) AU2015231180B2 (enExample)
BR (1) BR112016018813A2 (enExample)
CA (1) CA2943177A1 (enExample)
EA (1) EA201691634A1 (enExample)
IL (1) IL247048A0 (enExample)
MX (1) MX2016011102A (enExample)
SG (1) SG11201606521VA (enExample)
WO (1) WO2015143209A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2700651T1 (sl) 2008-07-18 2019-08-30 Bristol-Myers Squibb Company Monovalentni sestavki za vezavo CD28 in postopki uporabe
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
CA2963125A1 (en) 2014-09-30 2016-04-07 Bristol-Myers Squibb Company Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
AU2016360987A1 (en) * 2015-11-27 2018-06-07 Ablynx Nv Polypeptides inhibiting CD40L
US20190086405A1 (en) 2016-03-16 2019-03-21 Bristol-Myers Squibb Company Methods of diagnosing and treating lupus
MA50435A (fr) * 2017-05-24 2020-09-02 Als Therapy Development Inst Anticorps anti-ligand anti-cd40 thérapeutiques
JP7775080B2 (ja) * 2019-07-01 2025-11-25 トニックス ファーマ リミテッド 抗ｃｄ１５４抗体およびその使用
EP4688856A1 (en) 2023-04-03 2026-02-11 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
SG148143A1 (en) * 2003-11-04 2008-12-31 Novartis Vaccines & Diagnostic Antagonist anti-cd40 monoclonal antibodies and methods for their use
CN101198347A (zh) 2005-04-06 2008-06-11 布里斯托尔-迈尔斯斯奎布公司 使用可溶性ctla4突变型分子治疗与移植物移植有关的免疫病症的方法
TW200738261A (en) 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
SI2700651T1 (sl) 2008-07-18 2019-08-30 Bristol-Myers Squibb Company Monovalentni sestavki za vezavo CD28 in postopki uporabe
SMT202000091T1 (it) * 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l

Similar Documents

Publication Publication Date Title
JP2017509649A5 (enExample)
US20240174745A1 (en) Antibody Constructs for CLDN18.2 and CD3
CN111448211B (zh) 抗cd39抗体、包含抗cd39抗体的组合物和使用抗cd39抗体的方法
JP7682150B2 (ja) プロテアーゼ活性化治療剤を含む組成物および方法
JP7665600B2 (ja) 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法
JP2018502060A5 (enExample)
JP6763529B2 (ja) 抗クローディン−２モノクローナル抗体
SI2593128T1 (en) Humanized antibodies targeting the EC1 Kaderina-11 domain and associated compositions and procedures
KR20220019806A (ko) 가용성 보체 수용체 1형 변이체 접합체 및 이의 용도
AU2024239150A1 (en) Cd19/cd38 multispecific antibodies
KR20220159989A (ko) C19 c38 이중특이적 항체
JP2017524675A5 (enExample)
CA3238406A1 (en) Bispecific antibody and use thereof
US20230093169A1 (en) Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
CN103417965A (zh) 一种含有抗vegf抗体的药物组合物
CA3185332A1 (en) Recombinant rhabdovirus encoding for a cd80 extracellular domain fc-fusion protein
CA3107192C (en) Antibody constructs for cldn18.2 and cd3
WO2025174812A1 (en) Chimeric antigen receptor and/or synnotch receptor systems and cells and methods of their use
CN120437287A (zh) 一种包含特异性结合gucy2c和cd3的双特异性抗体的药物组合物
ES2860973T3 (es) Diacuerpos monovalentes biespecíficos que pueden unirse a CD123 y CD3 y usos de estos
WO2023036815A1 (en) Targeted regulation of platelet and megakaryocyte activation by heteroreceptor co-clustering